Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera

 Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera

Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion for Reduction of Kidney Exposure to Radiation During PPRT with Lutathera

Shots:

  • The positive opinion recommendation follows the study assessing arginine and lysine of same content as LysaKare, evaluating its safety and efficacy
  • The EC will review CHMP’s opinion with its expected results within three months, if approved will be a novel solution of this concentration available in EU  
  • LysaKare 25g/25g is a solution to reduce kidney exposure during PRRT with Lutathera (lutetium (177Lu) oxodotreotide) in adults. Lutathera is indicated to treat unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults and is approved as PPRT in EU in Sep 2017

Click here to read full press release/ article | Ref: Novartis | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post